Psoriasis: TNF-alpha inhibitors and beyond.
Kincaid
Lynne
L
Pharmaprojects, PJB Publications, 69-77 Paul Street, London EC2A 4LQ, UK. lynne.kincaid@informa.com
D016572:Cyclosporine / Q000627:therapeutic use; D004345:Drug Industry / Q000191:economics / Q000639:trends; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000037:antagonists & inhibitors; D009363:Neoplasm Proteins / Q000191:economics / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000191:economics / Q000379:methods / Q000639:trends*; D053319:Tumor Necrosis Factor Decoy Receptors
D009363:Neoplasm Proteins; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; C069521:recombinant human tumor necrosis factor-binding protein-1; C484071:voclosporin; D007334:Insulin-Like Growth Factor I; D016572:Cyclosporine